Intradermal Hepatitis B Vaccination in Non-Responder People Living with HIV in Japan.

抄録

We performed this pilot study to assess the immunogenicity and safety of intradermal hepatitis B (HB) virus vaccines in people living with HIV (PLWH). A single-center prospective study was conducted in Yokohama, Japan. Adult PLWH with serum antibodies against hepatitis B surface antigen (anti-HBs) < 10 mIU/mL at all the points after standard HB vaccination were included. We administered hepatitis B surface antigen (total dose 10 μg) at five separate sites intradermally at baseline, 1 month, and 6-9 months and measured anti-HBs 1-3 months after the administration. A total of 11 PLWH were included in this study. The mean age was 36 years, and all patients were male. At baseline, all patients were on anti-retroviral therapy, and the mean CD4 + lymphocyte count was 588 /μL and plasma HIV-RNA was below 20 copies/mL, except for one participant. Anti-HBs levels were elevated over 10 mIU/mL in one participant after one dose, six participants after two doses, and four participants after three doses of the intradermal vaccines. Eight participants experienced grade 1 local adverse event. Additional vaccination via intradermal route induced an anti-HBs level > 10 mIU/mL in all participants without serious adverse events.